Shohreh B. Eckhardt - Böcker
Visar alla böcker från författaren Shohreh B. Eckhardt. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
1 635 kr
Skickas inom 10-15 vardagar
In their novel approach to Drug Discovery, Maxwell and Eckhardt explore their thesis that the discovery of new drugs - especially of innovative therapeutic agents - is an independent dynamic process that demands the full attention of researchers, rather than a spontaneous consequence of investigative research. Faced with a dearth of quantitative information on how and where innovative drugs were discovered, the authors have developed considerable quantitative data about this process in order to provide a deeper understanding of its true nature. Drug Discovery: A Casebook and Analysis offers a unique quantitative survey of research since World War II that led to the development of 32 innovative therapeutic agents. Factual and concise, each chapter presents a review of the original scientific contributions associated with the discovery of a specific drug. These chapters are followed by a computer analysis of important variables and finally by an interpretation. Drug categories discussed include: cardiovascular and renal (including renal transplantation) psychiatric neurological rheumatological anesthesiological pulmonary gastrointestinal.Everyone interested in the basic or clinical research leading to important drugs - and the institutional interplay inherent in the process - will find Drug Discovery: A Casebook and Analysis a comprehensive, invaluable reference compendium!
1 635 kr
Skickas inom 10-15 vardagar
This treatise had its origins in the authors' strong opinion that the discovery of new drugs, especially of innovative therapeutic agents, really does not happen as a spontaneous sequel to investiga tive research, no matter how penetrating such research may be. Rather, it seemed to us that the discovery of innovative therapeutic agents was a very active process, existing in and of itself, and demanding full attention-it was not simply a passive, dependent by-process of investigative research. And yet, many researchers some close confreres of the authors, others more distant-believed otherwise. We felt that their view reflected unrealistic thinking and that reality probably lay closer to what Beyer" maintained: We are taught to believe that if we can understand a disease it should be easy enough to figure out, say, the molecular configuration of a definitive receptor mechanism somewhere along the line and to design a specific drug . . . . And so we start out to understand the disease but never get around to doing much about therapy. The authors very soon realized that there was essentially no quantitive information available on just where and how innovative therapeutic agents were discovered. There were only anecdotal accounts, and these were able to be selected and presented in ways that could be used to defend any point of view.